1. Search Result
Search Result
Results for "

phenotype

" in MedChemExpress (MCE) Product Catalog:

89

Inhibitors & Agonists

9

Screening Libraries

1

Fluorescent Dye

5

Biochemical Assay Reagents

3

Peptides

2

Inhibitory Antibodies

14

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0790
    Lupeol
    3 Publications Verification

    Clerodol; Monogynol B; Fagarasterol

    Androgen Receptor Apoptosis Cancer
    Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen receptor (AR) inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC) .
    Lupeol
  • HY-137892

    Epigenetic Reader Domain Inflammation/Immunology
    GSK620 is a potent and orally active pan-BD2 inhibitor with excellent broad selectivity, developability and in vivo oral pharmacokinetics. GSK620 is highly selective for the BET-BD2 family of proteins, with >200-fold selectivity over all other bromodomains. GSK620 shows an anti-inflammatory phenotype in human whole blood .
    GSK620
  • HY-145110

    IGF-1R Cancer
    IGF-1R inhibitor-2 (example 121) is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor. Downregulation of IGF-1R can reverse the transformed phenotype of tumor cells and potentially render them susceptible to apoptosis .
    IGF-1R inhibitor-2
  • HY-100384
    NKL 22
    1 Publications Verification

    HDAC Neurological Disease
    NKL 22 (compound 4b) is a potent and selective inhibitor of histone deacetylases (HDAC), with an IC50 of 199 and 69 nM for HDAC1 and HDAC3, respectively. NKL 22 exhibits selectivity over HDAC2/4/5/7/8 (IC50≥1.59 μM). NKL 22 ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice .
    NKL 22
  • HY-139990

    c-Fms Cancer
    CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity .
    CSF1R-IN-3
  • HY-120766

    Histone Demethylase Cancer
    NCDM-32B is a potent and selective KDM4 inhibitor that impaires viability and transforming phenotypes of breast cancer .
    NCDM-32B
  • HY-155762

    NOD-like Receptor (NLR) Interleukin Related Neurological Disease Inflammation/Immunology
    Anti-neuroinflammation agent 1 is a potent anti-neuroinflammation agent that regulates polarization BV2 microglia cells from M1 phenotype to M2 phenotype .
    Anti-neuroinflammation agent 1
  • HY-N0790R

    Androgen Receptor Apoptosis Cancer
    Lupeol (Standard) is the analytical standard of Lupeol. This product is intended for research and analytical applications. Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic?triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent?androgen receptor (AR)?inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC) .
    Lupeol (Standard)
  • HY-131954

    5-HT Receptor Neurological Disease
    5-HT3 antagonist 4 is a 5-HT3 receptor (5HT3R) antagonist. 5-HT3 antagonist 4 prevents diabetes-induced depressive phenotypes in mice .
    5-HT3 antagonist 4
  • HY-163642

    Others Cancer
    TNF-α agonistic 1 (compound 22a) can repolarize tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) from the M2 phenotype to the M1 anti-tumor phenotype .
    TNF-α agonistic 1
  • HY-N1363
    Royal Jelly acid
    4 Publications Verification

    Queen Bee Acid; (E)-10-Hydroxy-2-decenoic acid

    Endogenous Metabolite Neurological Disease
    Royal Jelly acid (Queen Bee Acid) is a fatty acid constituent of royal jelly, promotes the growth and protection of neurons, reduces anxiety-like phenotypes .
    Royal Jelly acid
  • HY-10996A

    FGFR Neurological Disease Cancer
    KHS101 hydrochloride could selectively induce a neuronal differentiation phenotype and interacts with transforming acidic coiled-coil-containing protein 3 (TACC3).
    KHS101 hydrochloride
  • HY-E70184

    EC:3.2.1.50; NAGLU; UFHSD 1

    Glucosylceramide Synthase (GCS) Others
    α-N-Acetylglucosaminidase (EC:3.2.1.50; NAGLU; UFHSD 1) is a alpha-N-acetylglucosaminidase .
    α-N-Acetylglucosaminidase
  • HY-136482

    Calcium Channel Others
    Nemadipine B is a calcium channel blocker and an EGL-19 antagonist. Nemadipine B induces Egl, Vab and Gro phenotypes in Caenorhabditis elegans .
    Nemadipine B
  • HY-B1378

    Calcium Channel Neurological Disease Cancer
    Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel.
    Ethosuximide
  • HY-104026B

    Endogenous Metabolite Aryl Hydrocarbon Receptor Inflammation/Immunology
    L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .
    L-Kynurenine sulfate
  • HY-124144

    Others Cancer
    MMV667492 is a potent Ezrin inhibitor with the activity to inhibit the invasion phenotype of osteosarcoma cells. MMV667492 exhibited potent anti-Ezrin activity in all biological assays and its compound properties were superior to NSC305787. MMV667492 was able to exhibit morphological defect phenotypes associated with Ezrin inhibition in zebrafish embryos. MMV667492 also showed the ability to inhibit the lung metastasis of osteosarcoma cells that highly expressed Ezrin .
    MMV667492
  • HY-121793

    (-)-Roemerine

    P-glycoprotein Endogenous Metabolite Cancer
    Roemerine, an aporphine alkaloid, isolated from the leaves of Fibraurea recisa Pierre, functions by interacting with P-glycoprotein. Roemerine reverses the multidrug-resistance phenotype with cultured cells .
    Roemerine
  • HY-Y0586

    Others Metabolic Disease
    2,4,5-Trimethoxybenzoic acid is a compound identified in purple perilla extracts. 2,4,5-Trimethoxybenzoic acid inhibits M1 macrophage phenotype-mediated inflammation in diabetes .
    2,4,5-Trimethoxybenzoic acid
  • HY-B1184
    Mephenytoin
    1 Publications Verification

    Cytochrome P450 Neurological Disease
    Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate .
    Mephenytoin
  • HY-B1184R

    Cytochrome P450 Neurological Disease
    Mephenytoin (Standard) is the analytical standard of Mephenytoin. This product is intended for research and analytical applications. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate .
    Mephenytoin (Standard)
  • HY-149711

    ICMT Metabolic Disease
    Farnesylcysteine (FC) is a competitive inhibitor of ICMT. The fcly mutant has quantitatively low farnesylcysteine (FC) lyase activity and an enhanced response to ABA. Farnesylcysteine induces an ABA hypersensitive phenotype in Arabidopsis thaliana .
    Farnesylcysteine
  • HY-B1378S1

    Isotope-Labeled Compounds Calcium Channel Neurological Disease
    Ethosuximide-d5 is deuterium labeled Ethosuximide. Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel.
    Ethosuximide-d5
  • HY-122604

    Others Neurological Disease
    PF-DcpSi is a mRNA decapping scavenger enzyme (DcpS) inhibitor (IC50: 0.11 nM). PF-DcpSi (30 mg/kg,i.p.) ameliorates the disease phenotype in a mice model of spinal muscular atrophy (SMA) .
    PF-DcpSi
  • HY-12346

    NSC 12407; BRD-K4477

    Others Others
    FH1 (NSC 12407) enhances hepatocyte functions, and promotes the differentiation of induced pluripotent stem (iPS)-derived hepatocytes toward a phenotype more mature and the maturation of well-differentiated cultures of hepatocyte-like cells (iHeps) .
    FH1
  • HY-122506

    STAT Cancer
    Salviolone is a natural diterpenoid derivative that can against melanoma cells. Salviolone exhibits a pleiotropic effect against melanoma by hampering cell cycle progression, STAT3 signaling, and malignant phenotype of A375 melanoma cells .
    Salviolone
  • HY-137206

    Ligands for E3 Ligase Molecular Glues Cancer
    ALV2 is a potent and selective Helios degrader. ALV2 binds CRBN, with an IC50 of 0.57 μM. Helios is the zinc-finger transcription factor that can maintain a stable Treg cell phenotype in the inflammatory tumor microenvironment .
    ALV2
  • HY-B1378S

    Isotope-Labeled Compounds Calcium Channel Neurological Disease
    Ethosuximide-d3 is the deuterium labeled Ethosuximide. Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel[1][2].
    Ethosuximide-d3
  • HY-B1378R

    Calcium Channel Neurological Disease Cancer
    Ethosuximide (Standard) is the analytical standard of Ethosuximide. This product is intended for research and analytical applications. Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel.
    Ethosuximide (Standard)
  • HY-P4340

    Cathepsin Cancer
    Arg-Arg-AMC is a highly selective substrate of Cathepsin B. Arg-Arg-AMC can be used to cathepsin B activity assay in cancer cells, while cathepsin B is assocaited with cell invasive and metastatic phenotype in numerous types of cancer .
    Arg-Arg-AMC
  • HY-125197

    Autophagy Inflammation/Immunology
    BRD5631 is an autophagy enhancer, enhances autophagy through an mTOR-independent pathway. BRD5631 affects several cellular disease phenotypes previously linked to autophagy, including protein aggregation, cell survival, bacterial replication, and inflammatory cytokine production .
    BRD5631
  • HY-104026CS

    Aryl Hydrocarbon Receptor Endogenous Metabolite Inflammation/Immunology
    L-Kynurenine- 13C10 (sulfate hemihydrate) is the 13C labeled L-Kynurenine sulfate. L-Kynurenine sulfate hemihydrate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .
    L-Kynurenine-13C10 sulfate hemihydrate
  • HY-139059

    Others Neurological Disease
    ERD03 is a potent disruptor of the EXOSC3-RNA interaction, with a Kd of 17±7 μM . ERD03 induces PCH1B-like phenotype in zebrafish embryo and can be used for neurological disorder disease research .
    ERD03
  • HY-117651

    Acyltransferase Cancer
    2-Fluoropalmitic acid, an acyl-CoA synthetase inhibitor, acts as a candidate anti-glioma agent. 2-Fluoropalmitic acid suppresses the viability and stem-like phenotype of glioma stem cells (GSCs). 2-Fluoropalmitic acid also inhibits proliferation and invasion of glioma cell lines .
    2-Fluoropalmitic acid
  • HY-169103

    NO Synthase COX Cholinesterase (ChE) Amyloid-β Neurological Disease Inflammation/Immunology
    Neuroprotective agent 5 (compound 28) is a brain permeabilizing agent with anti-neuritis, anti-oxidative damage and neuroprotective effects. Neuroprotective agent 5 exhibits a potent NO inhibitory effect (EC50=0.49 μM), inhibits the release of proinflammatory factors PGE2 and TNF-α, downregulates the expression of iNOS and COX-2 proteins, and promotes the polarization of BV-2 cells from the proinflammatory M1 phenotype to the anti-inflammatory M2 phenotype. In addition, Neuroprotective agent 5 can also inhibit acetylcholinesterase (AChE) activity and Aβ42 aggregation in a dose-dependent manner. Neuroprotective agent 5 can be used for the study of Alzheimer's disease .
    Neuroprotective agent 5
  • HY-131035

    Histone Acetyltransferase Cancer
    Lys-CoA TFA is a selective p300 histone acetyltransferase (HAT) inhibitor (IC50=50-500 nM). Lys-CoA TFA displays >100-fold selectivity for p300 over PCAF (IC50=200 μM). Lys-CoA TFA inhibits p300 HAT activity-dependent transcriptional activation .
    Lys-CoA TFA
  • HY-118134

    Others Cancer
    Hepln-13 is a potent and orally active Hepsin inhibitor with an IC50 of 0.33 µM. Hepln-13 can be used for the research of metastatic prostate cancer .
    Hepln-13
  • HY-125331

    Topoisomerase ADC Cytotoxin Cancer
    DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype .
    DRF-1042
  • HY-104026BS

    Aryl Hydrocarbon Receptor Endogenous Metabolite Inflammation/Immunology
    L-Kynurenine-13C10 (sulfate) is the 13C labeled L-Kynurenine sulfate. L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .
    L-Kynurenine-13C10 sulfate
  • HY-162939

    Histone Methyltransferase Cancer
    TB22 is a non-nucleoside inhibitor of DOT1LR231Q, possessing anticancer activity. TB22 inhibits the malignant phenotype of lung cancer cells carrying the R231Q mutation through the MAPK/ERK signaling pathway, and can be used for lung cancer research .
    TB22
  • HY-163172

    Others Neurological Disease
    Miro1 Reducer is a small molecule that can repair this defect of Miro1 in Parkinson's disease (PD) fibroblasts. Miro1 Reducer reduces the delayed mitophagy phenotype in PD fibroblasts. Miro1 Reducer reduces Miro1 protein levels in dose-dependent manner (IC50 = 7.8 mM) .
    Miro1 Reducer
  • HY-157955

    Trace Amine-associated Receptor (TAAR) Neurological Disease
    TAAR1 agonist 1 (compound 6E) is a potent TAAR1 agonist with a potent TAAR1-Gs/Gq dual-pathway activation property. TAAR1 agonist 1 significantly alleviates MK-801-induced schizophrenia-like cognitive phenotypes .
    TAAR1 agonist 1
  • HY-131448

    Others Metabolic Disease
    A3051 is a potent and orally active inhibtor of CXXC5-DVL extracted from patent WO2020079569, has an IC50 of 63.06 nM. A3334 can be used for the research of high fat diet (HFD)-induced and methionine-choline deficient diet (MCD)-induced phenotypes such as obesity, diabetes, and NASH .
    A3334
  • HY-P0119
    Lixisenatide
    2 Publications Verification

    GCGR MEK Akt MMP JNK Neurological Disease Metabolic Disease Inflammation/Immunology
    Lixisenatide is a GLP-1 receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of proinflammatory cytokines, and blocks of cellular signaling pathways. Lixisenatide decreases atheroma plaque size and instability in Apoe −/− Irs 2+/− mice by reprogramming macrophages towards an M2 phenotype, which leads to reduced inflammation .
    Lixisenatide
  • HY-N0284
    Esculetin
    4 Publications Verification

    PI3K Akt Inflammation/Immunology Cancer
    Esculetin is an active ingredient extracted mainly from the bark of Fraxinus rhynchophylla. Esculetin inhibits platelet-derived growth factor (PDGF)-induced airway smooth muscle cells (ASMCs) phenotype switching through inhibition of PI3K/Akt pathway. Esculetin has antioxidant, antiinflammatory, and antitumor activities .
    Esculetin
  • HY-169080

    Others Neurological Disease
    ABCA1 inducer 1 is a nonlipogenic ABCA1 inducer. ABCA1 inducer 1 increases ABCA1 expression, enhances apolipoprotein (APOE) lipidation and reverses multiple Alzheimer’s disease (AD) phenotypes, without increasing triglycerides in E3/4FAD mice that express human APOE 3/4 .
    ABCA1 inducer 1
  • HY-18620
    DZ2002
    1 Publications Verification

    Others Inflammation/Immunology
    DZ2002 is an orally active, reversible and low-cytotoxic type III SAHH inhibitor (Ki=17.9 nM), with good immunosuppressive activity. DZ2002 prevents the development of experimental dermal fibrosis by reversing the profibrotic phenotype of various cell types. DZ2002 can be used in studies of autoimmune diseases such as lupus syndrome and systemic sclerosis .
    DZ2002
  • HY-114250

    TRX-E-002-1

    Apoptosis Cancer
    Cantrixil (TRX-E-002-1), an active enantiomer of TRX-E-002, is a second-generation super-benzopyran (SBP) compound. Cantrixil increases phosphorylated c-Jun levels resulting in caspase-mediated apoptosis in ovarian cancer cells. Cantrixil has potent pan anti-cancer activity against a broad range of cancer phenotypes .
    Cantrixil
  • HY-P99256

    SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody

    Interleukin Related Inflammation/Immunology Cancer
    Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
    Tildrakizumab
  • HY-123298

    Src Akt Apoptosis Cancer
    Chrysotoxine is a dual inhibitor of Src/Akt. Chrysotoxine suppresses cancer stem cells (CSCs) phenotypes by down-regulating Src/Akt signaling. Chrysotoxine reduces cell viability and increases apoptosis level in H460 and H23 cells instead of non-tumor cell lines. Chrysotoxine shows rapid excretion and low bioavailability in rats. Chrysotoxine is used in cancer research .
    Chrysotoxine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: